Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
DBV Technologies S.A. (DBV.PA)
EUR2.76
-0.07 (-2.47%)
FR PAR Healthcare Biotechnology
Address
177-181 Avenue Pierre Brossolette 92120
Montrouge, FR
Montrouge, FR
CEO
Daniel Tassé
Website
dbv-technologies.com
IPO
2012-03-29
ISIN FR0010417345
Also trades on
Euronext Paris · DBV.PA (EUR)
NASDAQ Global Select · DBVT (USD)
Description
DBV Technologies S.A. is a clinical-stage biopharmaceutical company focusing on the research and development of epicutaneous immunotherapy products. Its flagship product candidate, Viaskin Peanut, an immunotherapy, has completed Phase III clinical trials and is designed to treat peanut allergies in children aged 4 to 11, as well as adolescents and adults. The company is also advancing Viaskin Milk, which is in Phase I/II clinical trials for Immunoglobulin E (IgE)-mediated cow's milk protein allergy (CMPA). Beyond this, its pipeline includes Viaskin Egg, a preclinical product for hen's egg allergy, and a booster vaccine for Bordetella pertussis. Further early-stage research programs are exploring a vaccine for respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. DBV is collaborating with Nestlé Health Science on MAG1C, a ready-to-use atopy patch test for diagnosing non-IgE mediated CMPA in infants and toddlers. Founded in 2002, DBV Technologies S.A. is headquartered in Montrouge, France.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
EUR2.76
-0.07 (-2.47%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
927.3K
Beta
-0.21
Float Shares
107.14M
Free Float %
63.4%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.06% | -0.46% | -0.46% | -5.58% | +42.20% | +3.08% | +79.59% | +4.94% | -65.81% | -93.41% | -61.20% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (13 ratings, all time)
Buy
Price Targets & DCF
Current price
2.76
DCF (Unlevered)
0.91
-67.2%
DCF (Levered)
1.05
-62.0%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
75% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 2 | 0 |
| Hold | 0 | 0 |
| Sell | 1 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
3.39
Safe zone
Piotroski F-Score
2 / 9
Weak
MOAT Score
1 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-100.0% Q1'26: -100.0% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+6.8% Q1'26: +57.7% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q1'26: +1,268.9% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+43.9% Q1'26: +317.4% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.15× Q1'26: -0.03× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 4 Rev. Ana. 2 EPS Ana. |
Dec 2027 6 Rev. Ana. 1 EPS Ana. |
Dec 2028 4 Rev. Ana. 1 EPS Ana. |
Dec 2029 3 Rev. Ana. 1 EPS Ana. |
Dec 2030 3 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
241.0K
est: 5.11M (-95.3%)
|
—
est: 11.91M (-100.0%)
|
—
est: 19.35M (-100.0%)
|
—
est: 16.89M (-100.0%)
|
—
est: 13.67M (-100.0%)
|
—
est: 13.31M (-100.0%)
|
5.71M
est: 5.41M (+5.6%)
|
4.80M
est: 6.35M (-24.4%)
|
15.73M
est: 14.85M (+5.9%)
|
4.15M
est: 2.32M (+78.9%)
|
—
est: 5.58M (-100.0%)
|
4.26M
2.68M – 5.65M
-23.7% YoY
|
119.02M
63.79M – 175.80M
+2,696.5% YoY
|
403.14M
217.54M – 593.07M
+238.7% YoY
|
852.59M
460.07M – 1.25B
+111.5% YoY
|
1.28B
688.15M – 1.88B
+49.6% YoY
|
| EBITDA |
-53.62M
est: -2.05M (-2,521.8%)
|
-126.29M
est: -4.76M (-2,550.3%)
|
-176.90M
est: -7.74M (-2,185.3%)
|
-206.16M
est: -6.75M (-2,952.2%)
|
-181.37M
est: -5.47M (-3,217.5%)
|
-162.74M
est: -5.32M (-2,957.3%)
|
-79.77M
est: -2.16M (-3,588.2%)
|
-76.68M
est: -2.54M (-2,917.6%)
|
-87.46M
est: -5.94M (-1,372.1%)
|
—
est: -928.3K (+100.0%)
|
-140.58M
est: -2.23M (-6,199.9%)
|
-1.70M
-2.26M – -1.07M
+23.7% YoY
|
-47.61M
-70.32M – -25.52M
-2,696.5% YoY
|
-161.26M
-237.23M – -87.02M
-238.7% YoY
|
-341.03M
-501.70M – -184.03M
-111.5% YoY
|
-510.10M
-750.42M – -275.26M
-49.6% YoY
|
| EBIT |
-48.68M
est: -3.07M (-1,486.9%)
|
-121.74M
est: -7.15M (-1,603.3%)
|
-153.70M
est: -11.61M (-1,223.7%)
|
-176.74M
est: -10.13M (-1,644.5%)
|
-162.57M
est: -8.20M (-1,882.5%)
|
-148.05M
est: -7.98M (-1,754.1%)
|
-89.04M
est: -3.24M (-2,644.6%)
|
-96.98M
est: -3.81M (-2,444.3%)
|
-75.37M
est: -8.91M (-745.7%)
|
-116.59M
est: -1.39M (-8,273.0%)
|
-158.92M
est: -3.35M (-4,647.8%)
|
-2.55M
-3.39M – -1.61M
+23.7% YoY
|
-71.41M
-105.48M – -38.27M
-2,696.5% YoY
|
-241.88M
-355.84M – -130.53M
-238.7% YoY
|
-511.55M
-752.55M – -276.04M
-111.5% YoY
|
-765.15M
-1.13B – -412.89M
-49.6% YoY
|
| Net Income |
-53.30M
est: -154.65M (+65.5%)
|
-126.35M
est: -554.36M (+77.2%)
|
-207.90M
est: -1.05B (+80.1%)
|
-227.00M
est: -955.22M (+76.2%)
|
-195.20M
est: -738.87M (+73.6%)
|
-195.68M
est: -466.96M (+58.1%)
|
-97.81M
est: -313.67M (+68.8%)
|
-96.30M
est: -167.67M (+42.6%)
|
-72.73M
est: -95.03M (+23.5%)
|
-113.92M
est: -32.20M (-253.8%)
|
-152.94M
est: -36.65M (-317.3%)
|
-28.17M
-45.11M – -11.23M
+23.1% YoY
|
-11.77M
-18.85M – -4.69M
+58.2% YoY
|
756.1K
301.5K – 1.21M
+106.4% YoY
|
12.56M
5.04M – 20.25M
+1,561.1% YoY
|
26.39M
10.60M – 42.56M
+110.1% YoY
|
| SGA |
20.61M
est: 22.02M (-6.4%)
|
50.86M
est: 51.29M (-0.8%)
|
72.13M
est: 83.33M (-13.4%)
|
98.20M
est: 72.71M (+35.1%)
|
79.85M
est: 58.85M (+35.7%)
|
53.98M
est: 57.30M (-5.8%)
|
34.91M
est: 23.28M (+49.9%)
|
25.90M
est: 27.35M (-5.3%)
|
22.88M
est: 63.96M (-64.2%)
|
31.40M
est: 9.99M (+214.2%)
|
29.43M
est: 24.02M (+22.5%)
|
18.33M
11.52M – 24.35M
-23.7% YoY
|
512.50M
274.68M – 756.97M
+2,696.5% YoY
|
1.74B
936.73M – 2.55B
+238.7% YoY
|
3.67B
1.98B – 5.40B
+111.5% YoY
|
5.49B
2.96B – 8.08B
+49.6% YoY
|
| EPS |
-2.48
est: -1.59 (-55.5%)
|
-5.17
est: -5.72 (+9.5%)
|
-8.40
est: -10.78 (+22.1%)
|
-7.85
est: -9.85 (+20.3%)
|
-5.28
est: -7.62 (+30.7%)
|
-3.62
est: -4.81 (+24.8%)
|
-1.78
est: -3.23 (+45.0%)
|
-1.24
est: -1.73 (+28.3%)
|
-0.71
est: -0.99 (+28.2%)
|
-1.17
est: -0.23 (-410.7%)
|
-1.09
est: -0.26 (-318.0%)
|
-0.20
-0.32 – -0.08
+23.1% YoY
|
-0.08
-0.14 – -0.03
+58.2% YoY
|
0.01
0.00 – 0.01
+106.4% YoY
|
0.09
0.04 – 0.15
+1,572.7% YoY
|
0.19
0.08 – 0.30
+110.1% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-08 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-04 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-30 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-29 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-28 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-27 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-24 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-23 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-17 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-16 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-143.48M
OE per share TTM
-1.15
Owner's Yield
-9.60%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
625.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 22 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | UBS MSCI EMU Small Cap UCITS ETF EUR dis UEFD.DE | 0.09% | 696.5K | 0.33% |
| 2 | iShares MSCI EMU Small Cap UCITS ETF CES1.L | 0.09% | 968.6K | 0.58% |
| 3 | iShares MSCI Europe Small-Cap ETF IEUS | 0.04% | 64.9K | 0.41% |
| 4 | Xtrackers MSCI Europe Small Cap UCITS ETF 1C XXSC.L | 0.04% | 1.25M | 0.30% |
| 5 | iShares Currency Hedged MSCI EAFE Small-Cap ETF HSCZ | 0.02% | 36.1K | 0.83% |
| 6 | iShares MSCI EAFE Small-Cap ETF SCZ | 0.02% | 2.18M | 0.40% |
| 7 | UBS MSCI EMU Select Factor Mix UCITS ETF EUR acc EUFM.L | 0.01% | 2.8K | 0.34% |
| 8 | Xtrackers MSCI Eurozone Hedged Equity ETF DBEZ | 0.01% | 6.1K | 0.45% |
| 9 | Goldman Sachs MSCI World Private Equity Return Tracker ETF GTPE | 0.01% | 2.2K | 0.50% |
| 10 | iShares MSCI World Small Cap UCITS ETF WSML.L | 0.00% | 414.1K | 0.35% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
Shares Outstanding
169.10M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Daniel Tassé | Chief Executive Officer & Director | 839.2K | male |
| Pharis Mohideen | Chief Medical Officer | 612.8K | — |
| Virginie Simone Jeanine Verrechia Boucinha | Chief Financial Officer | 344.9K | female |
| Kevin Malobisky | Chief Operations Officer | — | — |
| Alan Kerr | Senior Vice President & Head of Global Regulatory Affairs | — | — |
| Michele F. Robertson | Chief Legal Officer | — | female |
| Pascal Wotling | Chief External Manufacturing & Supply Chain Officer | — | male |
| Kevin Trapp | Chief Commercial Officer | — | male |
| James Briggs | Chief Human Resources Officer | — | male |
| Jonathan Neely | VP & Head of Investor Relations | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for DBV.PA
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
